A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

Multiple Brain Metastases Clinical Trial

Official title:

A Safety Lead-In/Randomized Phase 2 Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03608020
• Other study ID #: BMX-MBM-001
• Secondary ID: 1R44CA228694-01
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: October 4, 2018
• Est. completion date: April 15, 2024

Study information

• Verified date: April 2024
• Source: BioMimetix JV, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This protocol is for a lead-in safety study of 5 patients followed by a randomized Phase 2 clinical trial of BMX-001, a new class of pharmaceutical, in 64 patients with multiple brain metastases (MBM) undergoing whole brain radiation therapy (WBRT). Preliminary studies have demonstrated that BMX-001 provides protection of normal tissues from radiation-induced injury and augments tumor growth inhibition.

Description:

This protocol is for a Phase 1 safety lead-in clinical trial of BMX-001 in combination with WBRT in 5 patients with MBM. Demonstrating safety of the selected MTD of BMX-001 in patients with MBM undergoing standard protocol WBRT will be the "go/no-go" criteria for proceeding to Phase 2. Phase 2 is a randomized open-label Phase 2 clinical trial of 64 patients with MBM, half receiving BMX-001 in combination with WBRT and half receiving WBRT alone. Subjects are treated with BMX-001 for a total of 19 days, during which time they receive radiation therapy. Following completion of radiation therapy, subjects will be followed for an additional one year.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 35
• Est. completion date: April 15, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects must have histologically confirmed diagnosis of a non-small cell lung cancer, breast cancer, melanoma or renal cell cancer primary
• Subjects must have >5 contrast-enhancing lesions, never previously treated with SRS and/or surgical resection, on a contrast-enhanced T1-weighted brain MRI performed within two weeks of enrollment, with at least one lesion >0.5cm in greatest dimension
• Physical examination by a radiation oncologist or medical oncologist within 14 days of the start of WBRT
• Plan to be treated with WBRT to a dose of 30 Gy in 10 fractions
• Age * 18 years
• Karnofsky Performance Status (KPS) = 70
• Hemoglobin = 9.0 g/dl, ANC = 1,500 cells/*l, platelets = 125,000 cells/*l
• Serum creatinine = 1.5 mg/dl, serum SGOT and bilirubin = 1.5 times upper limit of normal
• Signed informed consent approved by the Institutional Review Board
• If sexually active, patients must agree to use appropriate contraceptive measures for the duration of the study and for 6 months afterwards as stated in the informed consent
• Able to provide study specific informed consent
• Willing to follow study procedures, complete QOL questionnaires and neurocognitive testing as described in the protocol
• Negative serum pregnancy test for women of child bearing potential within 48 hours of first dose of BMX

Exclusion Criteria:

• Active infection requiring IV antibiotics 7 days before enrollment
• Hypertension requiring 3 or more anti-hypertensive medications to control
• Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure
• History of syncope within the last 6 months
• Subjects receiving prohibited medications listed in Section 6.4.2 of this protocol are not eligible. Subjects who can safely stop taking a prohibited medication at least 7 days prior to the first dose of BMX may participate at the discretion of the treating physician.
• Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
• Women who are breast feeding
• Known hypersensitivity to compounds of similar chemical composition to BMX-001
• Prior surgical resection for brain metastases and/or stereotactic radiosurgery for up to 5 brain metastases in total are permitted if performed at least 1 month prior to planned WBRT under this protocol.
• Prior whole brain radiation therapy
• Patients with diffuse leptomeningeal disease (carcinomatous meningitis)
• A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >480 milliseconds (ms) (CTCAE grade 1)
• A history of additional risk factors for TdP (e.g., congestive heart failure, hypokalemia, known family history of Long QT Syndrome)

Related Conditions & MeSH terms

• Brain Neoplasms
• Multiple Brain Metastases
• Neoplasm Metastasis

Intervention

Drug:
• BMX-001
Manganese butoxyethyl pyridyl porphyrin

Radiation:
• Whole Brain Radiation Therapy
Whole Brain Radiation Therapy per standard of care.

Locations

Country	Name	City	State
United States	Henry Ford Hospital	Detroit	Michigan
United States	Duke Cancer Institute	Durham	North Carolina
United States	University of Kentucky	Lexington	Kentucky
United States	University of Washington	Seattle	Washington

Sponsors (3)

Lead Sponsor	Collaborator
BioMimetix JV, LLC	Duke Cancer Institute, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Compare rate of radionecrosis in WBRT + BMX-001 vs WBRT alone	Proportion of patients with enlarged and/or symptomatic brain lesions with no viable tumor on biopsy	1 Year
Other	Compare QoL in WBRT + BMX-001 vs WBRT alone	Mean change from baseline at each follow-up assessment	1 Year
Primary	Assess safety and tolerability of WBRT + BMX-001 through proportion of patients who experience grade 4 or 5 study drug related adverse events.	AEs will be assessed according to the CTCAE version 5.0. If CTCAE grading does not exist for an AE, the severity of the AE will be graded as mild (1), moderate (2), severe (3), life-threatening (4), or fatal (5). Initially 5 patients will be accrued and treated with WBRT + BMX-001 as a lead-in safety phase. Enrollment to the randomized phase of the study will not proceed if patients in the safety lead-in phase experience the following: Two or more patients are unable to complete radiation therapy (RT) due to toxicity related to BMX-001 (alone or in combination with RT.; Two or more patients experience delay in starting RT due to toxicity related to BMX-001 (alone or in combination with RT).; If any patient experiences a grade 4 or 5 BMX-001-related adverse event within Arm A (WBRT + BMX-001), accrual will be suspended and the experience of the patient will be carefully reviewed by the clinical team and the study's DSMB.	1 year
Primary	Compare neurocognition in WBRT + BMX-001 vs. WBRT alone using cumulative score of HVLT-R, TMT A&B and COWA over time.	Subjects will complete three standardized tests (Hopkins Verbal Learning Test - Revised, Trail Making Test A&B, and Controlled Oral Word Association test) at baseline, 1 month after completion of WBRT and every 3 months after completion of WBRT. The cumulative score of these three tests will be used to assess change.	1 Year
Secondary	Compare survival in WBRT + BMX-001 vs WBRT alone	Survival	1 Year
Secondary	Compare local recurrence rate in WBRT + BMX-001 vs WBRT alone	Median time to local brain failure or progression	1 Year
Secondary	Compare distant brain failure rate in WBRT + BMX-001 vs WBRT alone	Median time to distant brain failure	1 Year
Secondary	Compare rate of neurologic death in WBRT + BMX-001 vs WBRT alone	Proportion of patients who are dead within 1 year of initiation of WBRT due to neurologic disease and/or disseminated leptomeningeal carcinomatosis.	1 Year